SML2913
Dehydroxylcannabidiol
≥98% (HPLC)
Synonym(s):
2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentylphenol, DH-CBD
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C21H30O
CAS Number:
Molecular Weight:
298.46
UNSPSC Code:
12352200
NACRES:
NA.77
Recommended Products
Quality Level
Assay
≥98% (HPLC)
form
oil
optical activity
[α]/D -135 to -120°, c = 0.5 in chloroform-d
color
colorless to light brown
storage temp.
2-8°C
Biochem/physiol Actions
Dehydroxylcannabidiol (DH-CBD) is a synthetic nonpsychoactive cannabinoid that alleviate acute pain and chronic inflammatory pain by targeting α3 GlyRs. Dehydroxylcannabidio restores the function of both hyperekplexic mutant GlyRα1 and GABAAR in the presence of GlyRα1R271Q. Apparently dehydroxylcannabidiol interrupts the protein interaction GlyRα1 and GABAAR.
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Oral - Repr. 2
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Jieping Lu et al.
Neuropharmacology, 133, 224-232 (2018-02-07)
Some cannabinoids have been shown to suppress chronic pain by targeting glycine receptors (GlyRs). Although cannabinoid potentiation of α3 GlyRs is thought to contribute to cannabinoid-induced analgesia, the role of cannabinoid potentiation of α1 GlyRs in cannabinoid suppression of chronic
Wei Xiong et al.
The Journal of experimental medicine, 209(6), 1121-1134 (2012-05-16)
Certain types of nonpsychoactive cannabinoids can potentiate glycine receptors (GlyRs), an important target for nociceptive regulation at the spinal level. However, little is known about the potential and mechanism of glycinergic cannabinoids for chronic pain treatment. We report that systemic
Guichang Zou et al.
The Journal of biological chemistry, 295(1), 138-145 (2019-11-24)
The functions of the glycine receptor (GlyR) and GABAA receptor (GABAAR) are both impaired in hyperekplexia, a neurological disorder usually caused by GlyR mutations. Although emerging evidence indicates that cannabinoids can directly restore normal GlyR function, whether they affect GABAAR
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service